Advertisement

Recurrent Pneumonia and Fracture in the Femur

  • Selma Scheffler-Mendoza
  • Juan Carlos Bustamante-Ogando
  • Marco Yamazaki-Nakashimada
Chapter

Abstract

Autosomal dominant hyper IgE syndrome (AD-HIES) should be included in the differential diagnosis of severe eczema, elevated IgE, and recurrent infections in pediatric patients

AD-HIES is caused by STAT3 mutations, causing immunological and non-immunological clinical manifestation and is considered a multi-systemic disease

Primary objectives for treatment of AD-HIES should entail prevention of both infectious and non-infectious complications

A high index of clinical suspicion among primary care physicians and specialists other than immunologists is essential for AD-HIES diagnosis

Keywords

Hyper IgE syndrome Eczema STAT3 mutations 

References

  1. 1.
    Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25–32.CrossRefGoogle Scholar
  2. 2.
    Freeman AF, Holland SM. The hyper IgE syndromes. Immunol Allergy Clin N Am. 2008;28(2):277–91, viii.CrossRefGoogle Scholar
  3. 3.
    Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–19.CrossRefGoogle Scholar
  4. 4.
    Hsu AP, Davis J, Puck JM, et al. Autosomal dominant hyper IgE syndrome. 2010 Feb 23 [Updated 2012 Jun 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993–2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK25507/.
  5. 5.
    Paulson ML, Freeman AF, Holland SM. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. Curr Opin Allergy Clin Immunol. 2008;8(6):527–33.CrossRefGoogle Scholar
  6. 6.
    Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, Atkinson TP, Belohradsky BH, Buckley RH, Cossu F, Espanol T, Garty BZ, Matamoros N, Myers LA, Nelson RP, Ochs HD, Renner ED, Wellinghausen N, Puck JM. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65(3):735–44.CrossRefGoogle Scholar
  7. 7.
    Scheuerman O, Hoffer V, Cohen AH, Woellner C, Grimbacher B, Garty BZ. Reduced bone density in patients with autosomal dominant hyper-IgE syndrome. J Clin Immunol. 2013;33(5):903–8.CrossRefGoogle Scholar
  8. 8.
    Yavuz H, Chee R. A review on the vascular features of the hyperimmunoglobulin E syndrome. Clin Exp Immunol. 2010;159(3):238–44.CrossRefGoogle Scholar
  9. 9.
    Grimbacher B, Holland S, Gallin J, Greenberg F, Hill S, Malech H, Miller J, O’Connell A, Puck J. Hyper-IgE syndrome with recurrent infections: an autosomal dominant. N Engl J Med. 1999;340(9):692–702.CrossRefGoogle Scholar
  10. 10.
    Yong PFK, Freeman AF. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14(6):228.CrossRefGoogle Scholar
  11. 11.
    Minegishi Y, Saito M. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome. Ann N Y Acad Sci. 2011;1246:34–40.CrossRefGoogle Scholar
  12. 12.
    Bilora F, Petrobelli F, Boccioletti V, Pomerri F. Moderate-dose intravenous immunoglobulin treatment of Job’s syndrome. Case report. Minerva Med. 2000;91(5–6):113–6.PubMedGoogle Scholar
  13. 13.
    Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol. 1995;95(3):771–4.CrossRefGoogle Scholar
  14. 14.
    Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol. 1998;81(2):153–8.CrossRefGoogle Scholar
  15. 15.
    Walsh J, Reardon W. Job syndrome masquerading as non-accidental injury. Arch Dis Child. 2008;93:65–7.CrossRefGoogle Scholar
  16. 16.
    Staines Boone AT, Alcantara-Montiel JC, Sanchez-Sanchez LM, Arce-Cano M, Garcia-Campos J, Lugo Reyes SO. Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip. Pediatr Blood Cancer. 2016;63(11):2054–7.CrossRefGoogle Scholar
  17. 17.
    Elhasid R, Hofbauer LC, Ish-Shalom S, Ben-Arush M, Koc O, Rowe JM, Etzioni A. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. Am J Hematol. 2003;72(1):34–7.CrossRefGoogle Scholar
  18. 18.
    Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV—a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):446–51.CrossRefGoogle Scholar
  19. 19.
    Khan S. Abnormal IL-7 signaling may lead to the loss of bone mineral density in common variable immunodeficiency. Pediatr Allergy Immunol. 2012;23(2):202–3; author reply 4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Selma Scheffler-Mendoza
    • 1
  • Juan Carlos Bustamante-Ogando
    • 2
  • Marco Yamazaki-Nakashimada
    • 1
  1. 1.Immunology DepartmentNational Institute of PediatricsMexico CityMexico
  2. 2.Primary Immunodeficiencies Research Unit, National Institute of PediatricsMexico CityMexico

Personalised recommendations